Elthera: Groundbreaking tumor therapy - Novel target combined with state-of-the-art Mode of action
Beschreibung des Unternehmens
Unternehmensgegenstand (Geschäftskonzept, -idee)
Elthera AG is a Swiss Biotech company with the goal of developing an anti-L1CAM antibody based therapy for the treatment of pancreatic and ovarian cancer.
L1 cell adhesion molecule (L1CAM) is an adhesion molecule, which is expressed on many different tumor types, including ovarian, pancreatic, lung, breast, and colon cancer, as well as melanoma, glioblastoma, and others. It has been shown to promote tumor progression by a variety of different mechanisms, e.g. by directly stimulating tumor cell proliferation and the formation of metastases, by promoting angiogenesis in tumors, and by mediating resistance of tumor cells to chemotherapeutic agents.
L1CAM expression is associated with an aggressive tumor type and has been found to be a strong predictor for poor survival, underscoring its key role as a driver of the malignant process.
The Elthera AG product is based on a humanized affinity- and stability-optimized monoclonal antibody (mAb) against L1CAM. The humanized antibody has been used as a building block for the generation of two compounds with different therapeutic approaches, both inducing the targeted killing of cancer cells by two distinct mechanisms.
The first approach is an antibody drug conjugate (ADC). This targeted compound directs the linked cytotoxic agent at high concentrations to the tumor whereas systemic concentrations are low conferring to a favourable safety profile.
The second approach is a bispecific antibody, which recruits and activates cytotoxic T cells, the most efficient killer of the immune system through CD3 binding.
The therapeutic antibody will be developed in conjunction with a diagnostic method to identify the patients with L1CAM positive tumors. Efficient patient selection will reduce the costs of clinical trials and will increase the likelihood of therapeutic success in the treated patients.
Mehr über dieses Unternehmen
Möchten Sie mehr über dieses Unternehmen erfahren (u.a. Markt und Wettbewerb, Management und Mitarbeiter sowie Kapitalbedarf), dann müssen Sie sich hierzu einloggen oder anmelden.
Für kapitalsuchende Unternehmen und Business Angels / Investoren: Jochen Oelmann +49 (0)172 - 31 42 52 4
Für Kooperationspartner: Sebastian Pabst +49 (0)151 - 240 28 101
Venture Capital-/ Private Equity-Gesellschaften: